Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 18, Art. 33 (pp. 488-510)    |    2017       

»

Modern condition of treatment problems toxic hepatitis and fibros of liver

Orlov Y.V., Sinyachkin D.A., Khalimov Y.Sh., Antushevich A.E.

Brief summary

Fibrosis of the liver is the process of formation of connective tissue in the liver due to its damage. Fibrosis being a substratum for the development of major complications of liver cirrhosis (portal hypertension and hepatic-cell insufficiency) and having great importance for the formation of clinical manifestations of the disease, is not an independent pathological process but enters into a complex of morphological changes in the majority of chronic liver diseases. At present, in economically developed countries, 350 000 people die from chronic liver diseases, including cirrhosis. More often, cirrhosis develops against the background of prolonged alcohol intoxication and viral hepatitis B, C and D. The more rare causes of cirrhosis are biliary tract diseases, various chemical and drug intoxications. In the treatment of patients with liver cirrhosis, a major role is played by basic therapy of diseases that have led to the development of cirrhosis, as well as meajures for relief of the disease symptoms and prevention of complications. At the same time, specific therapy and effective prevention of chronic liver diseases are not currently developed. Existing schemes of therapy are not always effective and are characterized by a large number of contraindications and side effects. All these circumstances determine the relevance of the searching for new hepatoprotectors with various forms of administration (injectable and oral), which may reduce the duration of drug administrating and achieve the effect in a shorter period, by affecting pathogenetic mechanisms. At the moment, the most suitable drugs are ademethionine (heptral) and inosine glycyl-cysteinyl-glutamate disodium (molixane).


Key words

toxic hepatitis, liver fibrosis, hepatoprotectors, heptral, molixan.

Reference list

1. Abdyrahmanov D. T. Protivovirysnaya terapiya i regressiya fibroza pecheni pri hronicheskom gepatite V // Rossiiskii jyrnal gastroenter. gepatol. koloproktol. - 2010. - N1. - S. 14-20.


2. Abdyrahmanov D.E. Hronicheskii gepatit V // Klinicheskaya gepatologiya. - 2005. - N2. - S.20-28.


3. Aprosina Z.G. Aytoimmynnii gepatit// Prakticheskaya gepatologiya. Pod red. N.A. Myhina. - M., 2004.- S.101-105.


4. Assella T., Boier H., Gimont M.K. Pri hronicheskom virysnom gepatite S fibroz pecheni associirovan s virajennostu nekroza i vospaleniya, no ne so steatozom. // Gepatologiya.- 2003. - N6. - S.50-55.


5. Babah O.Ya. // Consilium Medicum. - 2001. - Ekstra vipysk. - S. 11-14.


6. Balabolkin M.I., Klebanova E.M. //Probl. endokrinol. - 2000. - N 6. - S. 29-34.


7. Baranova E. N. Cirroz pecheni, prognosticheskoe znachenie kliniko-vegetativnih pokazatelei // Tema dissertacii i avtoreferata po VAK 14.01.04, kandidat medicinskih nayk. Kemerovo-2013g. S-144.


8. Baranovskii A.U., Raihelson K.L., Marchenko N.V. // Primenenie S-adenozilmetionina (Geptrala?) v terapii bolnih nealkogolnim steatogepatitom. // Klinicheskie perspektivi gastroenterologii gepatologii 2010; 9 (1):3-10.


9. Beloborodova E.I., Saratikov A. S., Vengerovskii A.I., Shalovai A.A. //Klin, med.- 2000. - T. 78, Ns 6. - S. 56-57.


10. Belyakin S. A. Smertnost ot cirroza pecheni kak indikator yrovnya potrebleniya alkogolya v popylyacii / S. A. Belyakin, A. N. Bobrov // Vestnik Rossiiskoi voenno-medicinskoi akademii. - 2009. - T. 3. - S. 189-194.


11. Byeverov A.O. //Bolezni organov pishevareniya. - 2001. - T. 3, Ns 1. - S. 16-18.


12. Bichkova O.U., Savchenko V.N., Tomina E.E., Kartvelishvili A.U. Klinicheskaya farmakologiya gepatotropnih preparatov // Vestnik Harkovskogo nacionalnogo yniversiteta imeni V.N. Karazina. Seriya ?medicina?. - N 22 (975) / 2011


13. Galchenko O. E., V. A. Morozova, A. R. Babaeva//Sovremennie vozmojnosti primeneniya gepatoprotektorov v lechenii hronicheskih diffyznih zabolevanii pecheni// Lekarstvennii Vestnik N 2 (58) 2015 Tom 9, S. 7-17.


14. Gyndermann K. Noveishie dannie o mehanizmah deistviya i klinicheskoi effektivnosti essencialnih fosfolipidov // Klinicheskie perspektivi gastroenterologii, gepatologii. - Ns 2. - http://www.mtu-net.ru/rmvesti.


15. Ivashkin V .T. Bolezni pecheni i jelchevivodyashih pytei. Rykovodstvo dlya vrachei. - M.:M- Vesti, 2002. - 279 s.


16. Ivashkin V.T., Inozemcev S.A., Kyzmichev V.L. i dr. // Ross. jyrn. gastroenterol. gepatol. koloproktol. - 2004. - T. 14, Ns 1. - S. 41-46.


17. Kaliaskarova K.S., Baimagambetova J.B., Ymyrzakova R.S., Seidgaparova M.Y., Jysypbek S.J., Shevchenko S.A., Vasileva V.V., Vishnevskaya V.N. Sovremennie aspekti patogeneza virysnogo fibroza pecheni. // Klinicheskaya medicina Kazahstana N2 (25) 2012 S.89-92.


18. Kalinin A.V., Hazanov A.I. Alkogolnaya bolezn pecheni // Klinicheskie lekcii po gastroenterologii i gepatologii. - M., 2002. - S.127-163.


19. Klinicheskie rekomendacii. Standarti vedeniya bolnih. - M.: GEOTAR-Media, 2006. - 928 s.


20. Kryteckaya Z.I., Kyrilova L.S., Lebedev O.E., Kryteckaya N.I., Voicehovich K.O., Naymova A.A., Shamshev A.V.// Vliyanie disylfidsoderjashego preparata moliksan na vnytrikletochnyu koncentraciu Sa2+ v makrofagah.//Tezisi dokladov VIII mejdynarodnoi konferencii. Moskva, 4-6 oktyabrya 2010 g. M.: Rydn, 2010. 558 s.


21. Minyshkin O. N. Nekotorie gepatoprotektori v lechenii zabolevanii pecheni //Lechashii vrach. -2002-N6.-S. 55-58.


22. Minyshkin O.N. Galstena v lechenii nekotorih zabolevanii pecheni i jelchnih pytei // Klin, med,2001-T. 79, N12.-S. 38-41.


23. Novikov V.E:, Klimkina E.I. Farmakologiya gepatoprotektorov // Obz. klin, farmakol. lek. ter. - 2005. - T. 4, N 1 - S. 2-20.


24. Pavlov Ch.S. Principi diagnostiki i podhodi k terapii fibroza i cirroza pecheni // RMJ. 2007. N1. S. 11


25. Pavlov Ch.S., Shylpekova U.O., Zolotarevskii V.B. i dr. Sovremennie predstavleniya o patogeneze, diagnostike i lechenii fibroza pecheni//Rossiiskii jyrnal gastroenterologii, gepatologii, kolloproktologii. - 2005.- N2.- S.13-20.


26. Sadovnikova I. I. Cirrozi pecheni. Voprosi etiologii, patogeneza, kliniki, diagnostiki, lecheniya / I. I. Sadovnikova // RMJ. - 2003. - T. 5. - N 2. - S. 32-38.


27. Smirnov L.P., Syhovskaya I.V. //Rol glutationa v fynkcionirovanii sistem antioksidantnoi zashiti i biotransformacii (obzor).// Ychenie zapisi Petrozavodskogo gosydarstvennogo yniversiteta.- Sentyabr N 6- 2014.


28. Sovalkin V.I., Bikbavova G.R. Citokinovie mehanizmi v formirovanii vospalitelnih zabolevanii pecheni // Gepatologiya. - 2005. -N 1. - S. 4-7.


29. Spravochnik Vidal//Lekarstvennie preparati v Rossii // izdanie 22-2016g. - S.455-456.


30. Sutkin V.E. Sovremennie predstavleniya o fibroze pecheni // Gepatologicheskii forym. - 2007.- N2. - S.3-7.


31. Yshkalova E.A. Mesto essencialnih fosfolipidov v sovremennoi medicine // Farmateka. - 2003. - Ns 10. - S. 40-47.


32. Yshkalova E.A. Problemi primeneniya gepatoprotektorov // Farmateka. - 2004. - N 4. - S. 45-55.


33. Habriev R. Y. Rykovodstvo po eksperimentalnomy (doklinicheskomy) izycheniu novih farmakologicheskih veshestv / Pod obsh. red. chlen-korr. RAMN prof. R. Y. Habrieva. - 2-e izd., pererab. i dop. - M.: Medicina, 2005. - 832 s.


34. Shirokova E.N., Eshany V.S., Ivashkin V.T. Hofitol v terapii nealkogolnogo steatogepatita//Ross, jyrn. gastroenterol. gepatol. koloproktol. -2004-T. 14, Ns 2. - S. 74- 77.


35. Shylpekova U.O. Flavonoidi rastoropshi pyatnistoi v lechenii zabolevanii pecheni//Rysskii med. jyrn. - 2004. - T. 12, Ns 5. - S. 248-250.


36. Urev K.L. // Geptral? (ademetionin) - gepatoprotektor i antidepressant. // Ykrainskii medicinskii jyrnal N1 (87) I - II - 2012 g.: S 61-69.


37. Yakovenko E.P., Grigorev P.Ya. Geptral v lechenii vnytripechenochnogo holestaza // Ross. jyrn. gastroenterol. gepatol. koloproktol. - 2002. -T. 12, Ns 1. - S. 84-87.


38. Yakovenko E.P., Grigorev P.Ya. Hronicheskie zabolevaniya pecheni: diagnostika i lechenie // Rysskii med. jyrn. - 2003. - T. 11, Ns 5. - S. 291-296.


39. Yakovenko E.P., Grigorev P.Ya., Agafonova N.A. i dr. //Farmateka. - 2003. - Ns 10. - S. 47-52.


40. Afdhail N.H., Nunes D. Evalution of liver fibrosis: a concise review // Am. J. Gastroenterol. - 2004. N 99. - P.1160-1174.


41. Albanis E., Friedman S.L. Hepatic fibrosis Pathogenesis and principles of therapy // Clin. Liver. Disease - 2001. - N5. - P.315-334.


42. Angulo P. Treatment of nonalcoholic fatty liver disease// Ann. Hepatol. - 2002. -N 1. - P. 12-19.


43. Armstrong G.L. et al. The past incidence of hepatitis virus infection: implications for the future burden of chronic liver disease in the United States // Hepatology. - 2000. - N 38. - P.645-652.


44. Armstrong G.L., Alter M.J., McQuillan G.M. et al. The past incidence of hepatitis S virus infection: implication for the future burden of chronic liver disease in United States // Hepatology. - 2000. - N31. - P.777-782.


45. Brunt E.M. Nonalcoholic steatohepatitis // Semin. Liver dis. - 2004. - N24.- P.3-20.


46. Callewaert N., Van Vlierberghe H., Van Hecke A. et al. Noninvasive diagnosis of liver cirrhosis using DNA seguencer-based total serum protein glicomics // Nat. med. - 2004. - N10. - P.429-434.


47. Cuendet M., PezzutoM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention//Drug metabol. Drug interact. -2000. -N 17. -P. 109-157.


48. Desment V.J. Cirrhosis reversal: a duel between dogma and myth // J. Hepatology. - 2004. - N40.- P.860-867.


49. Dixon J.B., Bhathal P.S., Hughes N.R. Nonalcoholic fatty liver desease: Improvement in liver histo?logical analysis with weight loss // Hepatology. - 2004.- N39. - P1647-1654.


50. Geller S.A. Hepatitis V and S // Clin. Liver. Dis. - 2002. - N6. - P.317-334.


51. Gressner A.M., Weiskerhen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-(B as major players and therapeutic targets // J. Cell. Mol. Med. - 2006. - N10. - P.76-79.


52. Gressner A.M., Weiskerhen R., Breitkopf K. et al. Roles of TGF-p in hepatic fibrosis // Front. Biosci.- 2002. - N7. - P. 793-807.


53. Marra F., Efsen E., Romanelli R.G. et al. Ligands of peroxisom proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells // Gastroenterology. - 2000.-N.119. - P. 466-478.


54. Poynard Th. Handbook of liver disease // Churchill Livingstone. - 2004. - P.52-56.


55. Rala S.K., Gopumadhavan S., Venkataranganna M. V. et at. Protective effect ofLiv.52 on Na+/K+-ATPase activity in paracetamol-induced hepatotoxicity// Medicine Update. - 2002, - N 10.-P. 53-56.


56. Ziol M? Barget N., Sandrin L. et al. Correlation between liver elasticity measured by transient elas- tography and liver fibrosis assessed by morphometry in patients with HCV chronic hepatitis // J. Hepatol. - 2004. - N40. - P.136.